Pfizer Expands Anti-Infective Portfolio With $1.9 Bil. Vicuron Acquisition
This article was originally published in The Pink Sheet Daily
Executive Summary
Vicuron's near-term candidates include the antibiotic dalbavancin, which has a Sept 21 user fee deadline, and the antifungal anidulafungin, also pending at FDA. Pfizer's acquisition of Vicuron is expected to close in the third quarter.
You may also be interested in...
Durata Sets Sights On Commercialization As Dalbavancin Nears Filing
After completing an initial public offering in July, announcing plans to relocate its corporate headquarters to Chicago in November and releasing positive Phase III data on its lead drug, the antibiotic dalbavancin, Dec. 11, Durata Therapeutics is laying the groundwork to transition to a commercial drug company.
Durata Sets Sights On Commercialization As Dalbavancin Nears Filing
After completing an initial public offering in July, announcing plans to relocate its corporate headquarters to Chicago in November and releasing positive Phase III data on its lead drug, the antibiotic dalbavancin, Dec. 11, Durata Therapeutics is laying the groundwork to transition to a commercial drug company.
Dalbavancin Delay: Pfizer Pulls NDA To Conduct Extra Phase III Trial
Additional study for the antibiotic will take 18 months to complete, company says